Table 1.
Demographics, and outcome indices for patients after receiving the third infusion of scopolamine or placebo, as well as end of study remission and response rates.
| Treatment History | ||
|---|---|---|
| Treatment Naïve (n=31) | Treatment Resistant (n=31) | |
| Mean age ± SD | 31.45 ± 9.16 | 33.39 ± 9.83 |
| Gender (F) | 18 (58%) | 19 (61%) |
| Baseline MADRS ± SD | 30.55 ± 4.98 | 32.85 ± 4.39 |
| Duration of Illness (years) ± SD | 13.13 ± 10.78 | 14.13 ± 8.02 |
| Post-scopolamine | ||
| Full Response (≥50% reduction) | 13 (42%) | 10 (32%) |
| Partial Response (25%–49% reduction) | 9 (29%) | 6 (19%) |
| No Response (<25% reduction) | 9 (29%) | 15 (48%) |
| Remission (MADRS score ≤ 10) | 9 (29%) | 6 (19%) |
| Post-placebo | ||
| Full Response (≥50% reduction) | 2/14 (14%) | 0/18 (0%) |
| Partial Response (25%–49% reduction) | 3/14 (21%) | 5/18 (28%) |
| No Response (<25% reduction) | 9/14 (64%) | 13/18 (72%) |
| Remission (MADRS score ≤ 10) | 1/14 (7%) | 0/18 (0%) |
| End of study | ||
| Full Response (≥50% reduction) | 18 (58%) ** | 9 (29%) ** |
| Remission (MADRS score ≤ 10) | 13 (42%) * | 6 (19%) * |
Note: Response rates are given as number and percentage of patients. Placebo response rates include only subjects who received placebo in the first block.
*
trend level p< 0.10
**
significant p< 0.05